D

Dariusz M. Kowalski

The Maria Sklodowska-Curie National Research Institute of Oncology

ORCID: 0000-0002-9452-3229

Publishes on Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies. 331 papers and 28k citations.

PubIndex Score97Top 3%How it's scored

331Publications

28kTotal Citations

First publication: 1986First senior author: 1985

Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers Lung Cancer Research Studies Lung Cancer Diagnosis and Treatment Neuroendocrine Tumor Research Advances

Top publicationsby citations

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, David R. Gandara, Fabrice Barlési et al.|The Lancet|2016

Cited by 4.8k

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Nelly Cherciu, Kaoru Kubota et al.|The Lancet|2019

Cited by 3.3k

Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC

Masahiro Tsuboi, Yi‐Long Wu, Roy S. Herbst et al.|New England Journal of Medicine|2023

Cited by 605

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Lecia V. Sequist, Geoffrey R. Oxnard, Ji‐Youn Han et al.|The Lancet Oncology|2020

Cited by 413

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study

Martin Reck, Stephen V. Liu, Rafał Dziadziuszko et al.|Lung Cancer|2024

Cited by 66